Novel pharmaceutical compositions

Abstract

The invention relates to pharmaceutical compositions comprising dopamine transporter inhibitors and to their use in the prophylaxis or treatment of disease states or conditions mediated by the dopamine transporter.

1 . A pharmaceutical composition comprising a compound selected from: agatharesinol or a pharmaceutically acceptable derivative thereof; or kazinol U; or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein the compound is agatharesinol or a pharmaceutically acceptable derivative thereof, or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         3 . The pharmaceutical composition according to  claim 1 , wherein the compound is agatharesinol, or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         4 . The pharmaceutical composition according to  claim 1 , wherein the pharmaceutically acceptable derivative of agatharesinol is sequirin C, or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         5 . A pharmaceutical composition comprising a compound selected from: agatharesinol; sequirin C; or kazinol U; or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         6 . The pharmaceutical composition according to  claim 1 , wherein the compound is kazinol U, or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         7 . A pharmaceutical composition comprising a compound selected from: agatharesinol; or sequirin C; or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         8 . The pharmaceutical composition according to  claim 1 , which additionally comprises one or more pharmaceutically acceptable excipients. 
     
     
         9 . The pharmaceutical composition according to  claim 1 , in combination with one or more therapeutic agents. 
     
     
         10 . A method of inhibiting dopamine transporter activity, said method comprising contacting the dopamine transporter with a pharmaceutical composition according to  claim 1 . 
     
     
         11 . A method of treating a disease state or condition mediated by the dopamine transporter, said method comprising administering to a subject in need thereof the pharmaceutical composition according to  claim 1 . 
     
     
         12 . The method according to  claim 11 , wherein the disease state or condition mediated by the dopamine transporter is selected from: Parkinson's disease, bipolar disorder, clinical depression, attention deficit hyperactivity disorder (ADHD), narcolepsy, obstructive sleep apnea, night shift disorders, mood disorders, obesity, appetite suppression, cocaine addiction, methamphetamine addiction, antidepressant addiction, alcohol addiction and smoking addiction. 
     
     
         13 . The pharmaceutical composition according to  claim 2 , wherein the compound is agatharesinol, or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         14 . The pharmaceutical composition according to  claim 2 , wherein the pharmaceutically acceptable derivative of agatharesinol is sequirin C, or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         15 . The pharmaceutical composition according to  claim 5 , wherein the compound is kazinol U, or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         16 . The pharmaceutical composition according to  claim 5 , which additionally comprises one or more pharmaceutically acceptable excipients. 
     
     
         17 . The pharmaceutical composition according to  claim 5 , in combination with one or more therapeutic agents. 
     
     
         18 . A method of inhibiting dopamine transporter activity, said method comprising contacting the dopamine transporter with a pharmaceutical composition according to  claim 5 . 
     
     
         19 . A method of treating a disease state or condition mediated by the dopamine transporter, said method comprising administering to a subject in need thereof the pharmaceutical composition according to  claim 5 . 
     
     
         20 . The method according to  claim 19 , wherein the disease state or condition mediated by the dopamine transporter is selected from: Parkinson's disease, bipolar disorder, clinical depression, attention deficit hyperactivity disorder (ADHD), narcolepsy, obstructive sleep apnea, night shift disorders, mood disorders, obesity, appetite suppression, cocaine addiction, methamphetamine addiction, antidepressant addiction, alcohol addiction and smoking addiction.